Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
(NASDAQ: NTRA) Delayed: 212.07 -7.16 (3.27%)
Previous Close $219.23    52 Week High $13.80 
Open $223.71    52 Week Low $6.52 
Day High $223.71    P/E N/A 
Day Low $208.79    EPS $0.00 
Volume 811,715